On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National ...
In the most recent update to the National Comprehensive Cancer Network (NCCN) guidelines for treating patients who have multiple myeloma, a quadruplet regimen became the preferred first-line treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results